An Example of Personalized Treatment in HR+ HER2+ Long Survivor Breast Cancer Patient (Case Report).
BACKGROUND
Personalized therapy is becoming increasingly popular in oncological scenarios, not only based on molecular pharmacological targets, but also preventing any drug-drug-gene interaction (DDGI), which could lead to severe toxicities. Single nucleotide polymorphisms (SNPs), the individual germline sequence variations in genes involved in drug metabolism, are correlated to interindividual response to drugs and explain both efficacy and toxicity profiles reported by patients.


CASE PRESENTATION
We present the case of a woman suffering from triple-positive breast cancer; she had early-stage disease at the onset and after four years developed metastatic disease. During her history, she presented different toxicities due to antineoplastic treatments. Particularly, hypertransaminasemia was found during every line of treatment. Nevertheless, we were able to guarantee the patient an excellent therapeutic adhesion thanks to the supportive treatments and the reduction of drug dosage. Moreover, we conducted a simultaneous analysis of the patient's biochemical and genomic data thanks to Drug-PIN software, and we found several significant SNPs of the main enzymes and transporters involved in drug metabolism.


CONCLUSION
Our case report demonstrated the relevance of DDGI in clinical practice management of a patient treated for advanced breast cancer, suggesting the role of Drug-PIN software as an easy-to-use tool to prevent adverse events during cancer treatment and to help physicians in therapeutic algorithms. However, further studies are needed to confirm these results.
['Panebianco|Martina|M|', 'Taurelli Salimbeni|Beatrice|B|', 'Roberto|Michela|M|0000-0001-5339-8348', 'Marchetti|Paolo|P|0000-0002-9064-8761']
D000970:Antineoplastic Agents D001943:Breast Neoplasms D005260:Female D006801:Humans D057285:Precision Medicine D017741:Survivors
drug-drug-gene interaction (DDGI) single nucleotide polymorphisms (SNPs) HER2+ breast cancer hormone receptor positive (HR+)